Zhujiang Hospital,Southern Medical Universtiy
Guangzhou, Guangdong, 510282, China
NCT Number: NCT02296047
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity, mortality and disability throughout the world, leading to a heavy social and economic burden.Bronchodilators, the most commonly used drugs in COPD patients, have been shown to reduce dyspnea, improve exercise tolerance and improve health status. However,conventional lung function parameters such as forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) frequently fail to detect significant functional responses to bronchodilators in patients with chronic airflow obstruction. It is necessary for clinical and scientific reasons to develop a new tool to objectively assess the effect of different treatments including bronchodilator on COPD. Our previous study showed that Ventilation-drive coupling may be more sensitive and accurate to evaluate the efficacy of inhaled bronchodilators in patients with COPD because it could better reflect the pathological and physiological characteristics of COPD.
Based on the above conclusion, the present study were performed using the experimental methods of placebo and self-controlled. We aimd to explore the value of ventilation-drive coupling in evaluating the efficacy of bronchodilators on COPD and provide a reasonable basis for the clinical application of this index.
Looking for future studies?
Notify Me40 year–70 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510282, China
Patients were randomly assigned to one of two intervention groups:
The data were collected in 30 minutes after patients inhaled placebo,in 30 minutes after ipratropium and in 15 minutes after salbutamol.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients aged 40-70 years old; Patients with pulmonary function test of FEV1/FVC < 70% and FEV1%pred < 50%; Patients in a clinically stable state; Patients who signed informed consent.
Exclusion criteria
Patients with signs of an airway infection; Patients with an acute exacerbation during the previous 4 weeks; Patients with giant bulla(≥3cm in diameter); Patients with recent upper abdominal surgery; Patients with one or more of the following diseases: esophageal cancer, reflux esophagitis, severe obstructive sleep apnea (apnea hypopnea index>15/hr), neuromuscular disease, or significant heart failure; Patients with poor compliance.
physiological saline
Other names: Physiological Saline 9 mg/ml
80 µg inhalation once
Other names: atrovent
400 µg inhalation once
Other names: Ventolin
Time frame: The groups will be assessed at baseline (time zero) and ten minutes after using each drug.
Diaphragmatic function can be assessed by diaphragm electromyogram (EMGdi), which reflect the physiological activity of the diaphragm and indicate functional status of the central drive.
Time frame: The groups will be assessed at baseline (time zero) and ten minutes after using each drug.
Respiratory pressure parameters include gastric pressure (Pga), esophageal pressure (Pes), transdiaphragmatic pressure ( Pdi), mouth pressure (Pmo).
Time frame: The groups will be assessed at baseline (time zero) and ten minutes after using each drug.
Respiratory volume is associated with Flow, Inspiratory capacity (IC), tidal volume (VT), respiratory rate (RR), inspiratory time (Ti),expiratory time (Te), minute ventilation (VE).
Time frame: The groups will be assessed at baseline (time zero) and ten minutes after using each drug.
Difference in the degree of dyspnea can be measured by Borg index.
Zhujiang Hospital
Other
Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06040086
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Birmingham, Alabama, United States
View Trial DetailsNCT01917331
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Szeged, Hungary
View Trial DetailsNCT06897748
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Aramil, Russia
View Trial DetailsNCT04119934
Behavior, Chronic Disease
Toronto, Ontario, Canada
View Trial Details